**Svetol®, green coffee extract, induces weight loss and increases the lean to fat mass ratio in volunteers with overweight problem**

Dellalibera 0°, Lemaire B. and Lafay s·

o Ospedale SS. Antonio e Margherita, Dipartirnento Medico-Ambulatorio Obesita, Tortona, Italy

* Berkem®, Le Marais ouest, BP 4, 24 680 Gardonne, France

ABSTRACT

In order to test the effects of Svetol®, a green coffee extract rich in chlorogenic acids with specific ratio between 5-caffeoylquinic acid and others caffeoylquinic acid isomers, on weight loss, 50 volunteers with body mass index superior to 25 were selected. They were randomized in two groups, control group (n = 20) receiving placebo, treated group (n = 30) receiving Svetol®. Each volunteer took one capsule of Svetol® or placebo twice a day with main meal, for 60 days. Changes in weight, body mass index (BMl), Muscle Mass/Fat Mass ratio (MM/FM) and self-evaluation of physical aspect were recorded at TO and T60. After 60 days of treatment, a mean reduction in weight of 4.97 +/- 0.32 kg (5.7%) was observed in the Svetol® group compared to control

group in which the mean reduction was 2.45 +/- 0.37 kg (2.9%) (p < 0.001). Consequently, body mass index

decreased significantly in Svetol® group compared to control group. Moreover, MM/FM ratio was increased significantly in Svetol® group compared to control group: 4.1 +/- 0.7% *vs* 1.6 +/- 0.6 respectively (p = 0.01). The significant decrease of weight, boby mass index and fat mass showed that Svetol® is able to exacerbate effect of a bland low caloric diet in volunteers who have overweight. This effect could be explained by increasing the consumption of fatty deposits, as shown by change in the MM/FM ratio, and by preventing them from being accumulated.

To conclude, Svetol® could be used to aid the dietetics prescription in a useful and positive manner .

Key words: chlorogenic acids, Svetol®, weight , muscle mass/fat mass ratio

INTRODUCTION

Hydroxycinnamic acids are one of the major classes of phenolic compounds. They are present in a large variety of fruits and vegetables [1, 2]. The major representative of hydroxycinnamic acids in food is caffeic acid. It largely occurs conjugated with quinic acid as in chlorogenic acid (5-caffeoylquinic acid) **(Figure 1).** Coffee, one of the most widely consumed beverages in the world, is the major dietary source of chlorogenic acids.

Chlorogenic acid has antioxidant properties showed by its ability to scavenge various free radicals when tested *in vitro* [3-5]. Moreover , chlorogenic acid reduces glucose uptake by favouring the dissipation of the Na+ electrochemical gradient [6] and inhibits the activity of hepatic glucose-6-phosphatase which is implicated in glucose homeostasis [7, 8].

*In vivo,* when ingested under coffee form,

chlorogenic acid increases the plasma antioxidant capacity [9]. Chlorogenic acid is also able to reverse the prooxidant effects of drugs such as paraquat [10] and have been reported to prevent different cancers and cardiovascular diseases in several experimental studies on animal models [11- 15]. Therefore, we hypothesized that chlorogenic acid modulating glucose metabolism and decreasing oxidative stress could limit overweight, obesity development and secondary diseases

HOOC-Hc==Hc --0-OH

**B**

A

H900H O -<S-OH

3· c- c=c oH

••• / H H -

HO 0

OH

**Figure 1:** Chemical structure of caffeic (A) and chlorogenic acids (B)

associated with as type 2 diabetes mellitus or cardiovascular problems.

The aim of the present work was to evaluate if Svetol®, a green coffee extract, could decrease overweight in volunteers who had body mass index (BMl) superior to 25.

SUBJECTS AND METHODS

**Chemicals**

Svetol®, decaffeinated ireen coffee extract, were purchased from Berkem SA (Gardonne, France).

Subjects

Fifty volunteers of both sexes, aged from 19 to 75, were assigned at random to the group of 30 in active treatment , and 20 in placebo treatment. The participants of both groups were homogeneous in weight and muscle mass/fat mass (MMIFM) ratio, characterized by an overweight problem , BMI superior to 25, and the acceptance of a bland low caloric diet. Exclusion criteria were as follows: acute or chronic gastro-intestinal pathologies; gastro-intestinal infections and/or pamsitosis; severe hyper-tension (P.A. above 120 mm.); gastro­ intestinal cancers; serious or chronic metabolic pathologies; big drinkers; assumption of products for the control of weight and glycaemia ; a known intolerance to any of the components of the product under examination.

Svetol® supplementation

The product was prepared in jars of 30 capsules absolutely identical. Composition of the product (active capsules) under experimentation was given in table I. Placebo capsules contained the same components as the active capsule, Svetol® was substituted by an identical quantity of maltodextrin (200 mg).

mg/capsule

aspect was done by scale from 0 = very negative to 10 = excellent.

Evaluation of effectiveness, compliance and

tolerability

At the end of treatment, effectiveness , compliance and tolerability were verified with regard to the end-points by comparing the changes in the data recorded at T60 to those at TO.

Therefore, changes of weight, BMI, MMIFM ratio,

self-evaluation of physical aspect in the active group were compared to those recorded in the placebo group.

The effectiveness was based on those participants who completed the study. Compliance and tolerability were based on all participants .

Statistical analysis

Numerical values are mean +/- SEM (n = 20 for control group or 30 for treated group). Data were entered into Instat statistical analysis program (Instat, San Diego, CA). Student t-test (parametric test) or Mann-Whitney test (non-parametric test) detennined the difference between values. Differences with p :=:; 0.05 were considered significant.

RESULTS

Weight loss and Body Mass Index

Svetol®

Starch

Magnesium stereate Silica micronized White gelatine

200

0.04

0.015

0.008

0.087

After 60 days of treatment, a mean reduction in weight of 4.97 +/- 0.32 kg (-5.7 +/- 0.3%) was observed in the Svetol® group compared to control group in which the mean reduction was 2.45 +/-

0.37 kg (-2.9 +/- 0.4%). These means are

Table 1: Composition of the SvetoJ® capsule

Study design

Volunteers took one capsule with each main meal , twice a day, for 60 days. Every participant was given treatment sufficient for 30 days (two jars) when they began the study (TO) and the rest (two jars) at the T30 day.

Data collection and parameters of evaluation

In the course of the first check-up, the following data were gathered : age, height, sex, weight, BMI, MMIFM ratio, self-eva luation of physical aspect. Changes in weight, BMI, MMIFM ratio, self­ evaluation of physical aspect were recorded again at T60. An evaluation of compliance and verification of the presence of side effects was undertaken at T30 and T60.

MM/FM ratio was determined by Bioelectric Impedance Analysis. Self-evaluation of physical

significantly different (p < 0.001) (Figure 2A). Consequently, body mass index decreased significantly in Svetol® group compared to control group (-1.9 +/- 0.1 kg/m2 *vs* -0.9 +/- 0.1 kg/m2 ; p < 0.001 ) (Figure 2B).

Muscle Mass/ Fat Mass ratio

In Svetol® group, MMIFM ratio was increased significantly compared to control group: +4.1 +/- 0.7% *vs* + 1.6 +/- 0.6 respectively (p =0.01)

(Figure 3).

Self-evaluation of physical aspect

No significant difference about the appearance was observed between both groups at T60 (6.6 +/- 1.05 *vs 6.5+1-* 1.31 for placebo and Svetol® groups respectively) but both groups observed an amelioration of the physica l appearance between TO and T60 (p < 0.05 for each group).

**A** ,.-,

# .,

'-'

**.E**"'

**.**..**c**..

e.!)

**·as**

##### 0

-2

r::J Control

**n:::::J** Svetol®

**-4**

##### -6

not simple so in order to reach the desired goal of controlling weight pharmaceutical products are used as well as nutritional supplements with various compositions, fat burners , all with the aim of contrasting the lack of balance between the number of calories introduced and the number of those consumed which leads to overweight. There is a relationship between the amount of carbohydrates in the diet and the amount of fats in the adipose reserves since the carbohydrates are responsible for

**B** ..,.. , 0

**E**

en

..:.::

..=...

'-'

;.< **-1**

= =

**"'"C**

#### f!-

(J "'

=

###### -2

;;..,

\*\*\*

·:

I •

# L-f--

c=J Control

**E=:J** Svetol®

of sugars reduces energy consumption. In normal production and activity of insulin, the calories introduced are burnt up without transforming the lipids into stock. On the other hand, if the amount of glucose present in the blood is in excess with regards to its use and to the hepatic glycogenesis, this excess glucose (owing to the insulin which has been increased by the hyperglycemia) enters into

the adipocytes where it is stored as fat reserves

**"C**

==

\*\*\*

[18]. The consequences are: (i) the fat reserves are not used to produce energy; (ii) an increase of

,.-,

###### -.?.

'-'

**Figure 2:** (A) Weight loss(%) and (B) decrease of

BMI (kg/m2) after 60 days treatment. Values are

means +/- SEM, n = 20 for control group, n = 30

for Svetol® group. Means are significantly different

(\*, p < 0.001 vs. control group).

6

adipocytes.

In diets the lower quantity of carbohydrates consumed is a way to "force" the organism to burn up the fat which has been deposited in the adipocytes and therefore to lose weight. It is possible to improve the effect of the lower amounts

of carbohydrates consumed by exploiting the

..=...

**.5**=**!**

....

"=' 5 \*\*

.=... **4**

hepatic activity to regulate the glycemia level. When glucose level in the blood is lower than lg/L, the liver synthesized glucose-6-phosphate (G6P) by

**.**=**i:** -;,; 3

= "='

>

###### 2

**<:l**

"**:::1**' 1

0

L Control

**E=:J** Svetol®

an hexokinase, hydrolysed G6P by means of a glucose-6-phosphatase and released glucose into the bloodstream. It's glycogenolysis. If this sequence is interrupted the fatty deposits do not increase, but are instead used for the production of energy.

The aim of the present work was to evaluate if

Svetol®, green coffee extract concentrated in

**Figure** 3: Variation of muscle Mass/ fat Mass ratio after 60 days of treatment (%). Values are means +/- SEM, n = 20 for control group, n = 30 for Svetol® group. Means are significantly different(\*\*, p = 0.01 vs. control group).

DISCUSSION

Obesity is a serious public health problem [16]. Overweight and obesity are the cause of health problems of varying degrees of seriousness: asthenia, osteo-arthicular , psychological and cardio­ vascular problems.

The reality is that this condition has a negative impact on the quality of life, and in the case of obesity, it can even lead to a reduction in life expectancy.

With the exception of serious neuro-endocrine pathologies the problem is caused mainly by lifestyle. A rational diet in quantity and quality, combined with some physical exercise can help to obtain some loss of weight. A change in lifestyle is

chlorogenic acids with specific ratio between 5- caffeoylquinic acid and others caffeoylquinic acid isomers, could decrease overweight in volunteers by fat burning action as suggested by *in vitro* studies showing inhibition of the activity of hepatic glucose-6-phosphatase by 5-caffeoylquinic acid [7, 8].

The significant decrease of weight and fat mass showed that Svetol® is able to exacerbate effect of a bland low caloric diet in volunteers who had overweight. This effect could be explained by increasing the consumption of fatty deposits, as shown by change in the MM!FM ratio, and by preventing them from being accumulated.

From results presented here and bibliography, Svetol®'s mechanism could be proposed: first of all, associated with the diet, it inhibits glucose absorption in the small intestine[6]. In addition , by inhibiting the activity of glucose-6-phosphatase [7, 8], it limits the release of glucose into the general circulation [19, 20] and therefore limits

insulinemia . This mechanism engenders two results: (i) less fatty deposits in the adipose tissue and a more difficult access into the adipose cells owing to a reduction in insulin activity; (ii) consumption of fat reserves , where there is a lack of glucose, as a source of energy at the disposition of the organism and therefore, as in the previous case, a case of loss of weight.

However, mechan ism proposed depends on bioavailability of chlorogenic acid. Recently, fate and metabolism of chlorogenic acid (5- caffeoylquinic acid) in the gastro-intestinal tract of rats were explored to determine the form under which this ester of caffeic acid is absorbed through the different parts of the gut barrier.

After analysis of the different gastro-intestinal contents, it appeared that chlorogenic acid is stable in the stomach and the small intestine but cleaved into caffeic acid in the caecum by the rnicroflora [21]. Consequently, stability of chlorogenic acid in the small intestine is coherent with glucose absorption inhibition in this part of the gut. Moreover, whereas it was shown that chlorogenic acid was hydrolysed into enterocytes before secretion on the serosal side [22], it was absorbed under intact form from the stomach (21) and found in gastric vein and aorta without conjugation (glucuronidation, sulfation or methylation). This result suggests that chlorogenic acid is able to rejoin the liver without modification , which is in accordance with its activity of hepatic glucose-6- phosphatase inhibition.

Thus, cblorogenic acid bioavailability studies

supported Svetol®'s mechanism proposed .

To conclude, Svetol® bas demonstrated its validity and could be used to aid the dietetics prescription in a useful and positive manner.

BIBLIOGRAPHY

1. Clifford, M.N., Chlorogenic acids and other cinnarnates - Nature, occurence and dietary burden. J. Sci. Food. Agric., 1999. 79: p. 362-372.
2. Manach, C., et a!., Polypbenols - Food sources and bioavailability. Am. J. Clin. Nutr. , 2004. 79(5): p. 727-747.
3. Ohnishi, M., et a!., Inhibitory effects of chlorogenic acids on linoleic acid peroxidation and haemolysis. Phytochemistry , 1994. 36(3): p. 579-583.
4. Rice-Evans, C.A., N.J. Miller, and G. Paganga, Structure-antioxidant act1v1ty relationships of flavonoids and phenolic acids. Free Rad. Bioi. Med., 1996. 20(7): p. 933-956.
5. Foley, S., eta!., Singlet oxygen quenching

and the redox properties of

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

bydroxycinnamic acids. Free Radic Bioi Med, 1999. 26(9-10):p. 1202-8.

Welsch, C.A., P.A. Lachance, and B.P.

Wasserman, Dietary phenolic compounds: inhibition of sodium-dependant D-glucose uptake in rat intestinal brush border membrane vesicles. J. Nutr. , 1989. 119(1 1): p. 1698-1704.

Arion, W.J., et a!., Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Arch Biocbem Biophys, 1997. 339(2): p. 315-

22.

Hemmerle, H., eta!., Chlorogenic acid and synthetic cblorogenic acid derivatives: novel inhibitors of hepatic glucose-6- phospbate translocase. J Med Chern , 1997. 40(2): p. 137-45.

Natella, F., et al., Coffee drinking influences plasma antioxidant capacity in humans. J Agric Food Chern, 2002. 50(21): p. 6211-6.

Tsucbiya, T., 0. Suzuki, and K. Igarashi,

Protective effects of cblorogenic acid on paraquat-induced oxidative stress in rats. Biosci Biotechnol Biochem, 1996. 60(5):

p. 765-8.

Mori, H., et a!., Inhibitory effect of chlorogenic acid on methylazoxymethanol acetate-induced carcinogenesis in large intestine and liver of hamsters. Cancer Lett, 1986. 30(1): p. 49-54.

Tanaka, T., et a!., Inhibition of 4- nitroquinoline-1-oxide -induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids. Carcinogenesis , 1993. 14(7): p. 1321-5. Tanaka, T., et a!., Inhibitory effects of chlorogenic acid, reserpine, polyprenoic acid (E-5166), or coffee on hepatocarcinogenesis in rats and hamsters. Basic Life Sci, 1990. 52: p. 429-40.

Zhou, J., et a!., Protective Effect of Cblorogenic Acid on Lipid-Peroxidation Induced in the Liver of Rats by Carbon­ Tetrachloride or Co-60-Irradiation. Journa l of Clinical Biochemistry and Nutrition , 1993. 15(2): p. 119-125.

Suzuki, A., et al., Green coffee bean extract and its metabolites have a hypotensive effect in spontaneously hypertensive rats. Hypertension Research, 2002. 25(1): p. 99-107.

Guy-Grand , B., Obesite: genetique, pbysiopathologie et therapeutique a l'aube d'une revolution conceptuelle . 2005:

lnstitut Pasteur, Centre d'information

scientifique.

1. Liotta, S., Obesita e le adiposita

localizzate . 1974, Roma.

1. Anthoni, C. and N. Kolthoff, Fondamenti di anatomia e fisiologia dell'uomo, C.E. Ambrosina, Editor. 1977: Milano . p. 433.
2. Herling, A.W., et al., Pharmacod ynamic profile of a novel inhibitor of the hepatic glucose-6- phosphatase system. Am J Physiol, 1998. 274(6 Pt 1): p. 01087-93.
3. Simon, C., et al., Upregulation of hepatic glucose 6-phosphatase gene expression in rats treated with an inhibitor of glucose-6- phosphate translocase. Arch Biochem Biophys, 2000. 373(2): p. 418-28.
4. Lafay , S., et al., Chlorogenic acid is absorbed in its intact fonn in the stomach ofrats. J. Nutr, 2006. 136(5); 1192-1197
5. Lafay, S., et al., Absorption and metabolism of caffeic acid and chlorogenic acid in the small intestine of rats. Br. J. Nutr, 2006. under press.

JOURNAL OF

**AGRICULTURAL AND FOOD CHEMISTRY** ARTICLE

*J. Agric. Food Chem.* XXXX ,*XXX,* 000-000 A

001:10.1021(]19044827

**Contribution of Chlorogenic Acids to the Inhibition of Human Hepatic Glucose-6-phosphatase Activity in Vitro by Svetol, a Standardized Decaffeinated Green Coffee Extract**

CAROLINE HENRY-VITRA C,t ALVIN IBARRA,§ MARC ROLLER ,#

JEAN-MICHEL MERILLON,t AND XAVIER VITRA C\*,t

tPolyphenols Biotech EA 3675, Universite Victor Segalen Bordeaux 2, Institut des Sciences de Ia Vigne et du Yin, 210 Chemin de Leysotte, 33140 Villenaved 'Ornon, France , at urex Inc., 375Huyler Street, South Hackensack, New Jersey 07606, and atu rex SA Site d'Agroparc, B.P. 1218, 8491 1 Avignon Cedex 9, France

Glucose-6-phosphatase (Gic-6-Pase) is a multicomponent system that exists primarily in the liver and catalyzes the terminal step in gluconeogenesis and glycogenolysis. Several studies have attempted to identify synthetic or natural compounds that inhibit this enzyme complex for therapeutic use in regulating blood glucose and type 2 diabetes. For this paper an in vitro structure -activity relationship study of several natural chlorogenic acids was conducted, and the active components of the natural decaffeinated green coffee extract Svetol were identified. Glucose-6-phosphate (Gic-6-P) hydrolysis was measured in the presence of Svetol or chlorogenic acids in intact human liver microsomes. Svetol significantly inhibited Glc-6-P hydrolysis in intact human liver microsomes in a competitive manner, and it was determined that chlorogenic acids (caffeoylquinic acids and dicaffeoylquinic acids) were the chief compounds mediating this activity. In addition, the structure ­ activity analysis showed that variation in the position of the caffeoyl residue is an important determinant of inhibition of Glc-6-P hydrolysis. This inhibition by Svetol contributes to its antidiabetic , glucose-lowering effects by reducing hepatic glucose production.

KEYWORDS: Decaffeinated green coffee extract; Svetol; chlorogenic acids; glucose-6-phosphatase

INTRODUCTION

Coffee is one of the world's most popular beverages. The numerous beneficial health effects of coffee consumption have received significant scientific attention recently, because the results of epidemiological and experimenta l studies suggest that drinking coffee regularly helps prevent several chronic diseases, especially metabolic disorders, such as type 2 diabetes *(1-3).* Extensive investigations have revealed that most of these effects are attributed to the chlorogenic acids (CGAs) in coffee *(4).*

Green (or raw) coffee is a significant source ofCGAs in nature (5-12 g/ 100 g) (5). In green coffee, the primary CGAs are 3-, 4-, and 5-caffeoylquinic acids (CQA) and 3,4-, 3,5-, and 4,5-di caf­ feoylquinic acids (diCQAs). Caffeoylferuloylquinic acids (FQAs) are minor CGA compounds also found in green coffee *(6).*

Weight loss is linked to the capacity of coffee to prevent type 2 diabetes; one prospective epidemiological study found that the consumption of coffee lowered the risk for diabetes, but only in participants who had lost weight (7). Two clinical studies distin­ guished the effects of caffeinated and decaffeinated coffee *(8,9)* and suggested that there are noncaffeine compounds in coffee, such as CGAs, that enhance glucose tolerance and insulin sensitivity. In a recent study, Dellalibera et a!. showed that

\*Corresponding author (telephone (33)5 57 57 59 70; fax (33)5 57 57

59 52; e-mail xavier.vitrac@u-bordeaux2.fr].

©XXXX American ChemicalSociety

chronic consumption of Svetol, a decaffeinated green coffee extract that has high CGA content, decreased weight and increased lean/fat ratios in overweight volunteers *(10).*

One proposed mechanism of such effects is inhibition of glucose-6-phosphatase (Glc-6-Pase; EC 3.1.3.9), which forces lipids to be used as energy to compensate for the decrease in glucose release from glycogenolysis. Liver Glc-6-Pase is a multi­ component system that catalyzes the final step of hepatic glucose production , that is, the hydrolysis of glucose-6-phosp hate (Glc-6-

P) from glycogen breakdown or gluconeogenesis. The active site of Glc-6-Pase is in the lumen of the endoplasmic reticulum (ER); therefore, transporter proteins are required to shuttle Glc-6-P into this compartment and expel glucose and phosphate *(11).*

Glc-6-P hydrolysis appears to involve a Glc-6-P translocase (Glc-6-PT), which transports Glc-6-P across the ER, and a catalytic subunit, located on the luminal side of the ER *(12).* 5- CQA is a highly specific inhibitor ofGlc-6-Pase *(13),* and several analogues of 5-CQA that effect greater inhibition (e.g., S3483) have been synthesized; they increase the latency of Glc-6-Pa se by reducing its activity in intact microsomes or in the intact ER in situ *(14).*

The aim of this study was to determine the inhibitory activity of Svetol, a decaffeinated green coffee extract that has a specific ratio between 5-CQA and other CGAs, on Glc-6-P hydrolysis in intact human liver microsomes. In addition, we report the

pubs.acs.org/JAFC

**8** *J. Agric. Food Chem.,* Vol. XXX, No. XX, XXXX

Table 1. Chlorogenic Acid Content in Svetol"

compound typical content in Svetol (%) sample(%)

3-CQA 6.53±0.54 6.61

4-CQA 7.31 ± 0.43 7.66

5-CQA 14.72± 1.07 13.83

3,4-diCQA 3.57 ±0.54 3.34

3,5-diCQA 2.38±0.08 2.38

4,5-diCQA 4.22±0.15 4.15

3-FQA 1.28±0.11 1.30

4-FQA 1.50±0.23 1.87

5-FQA 3.39± 0.36 3.39

3,4-caffeoylferuloylquinic acid 0.67±0.06 0.77

3,5-caffeoylferuloylquinic acid 0.30± 0.02 0.31

4,5-caffeoylferuloylquinic acid 0.30±0.29 0.81

caffeoyltryptophan 1.00±0.80 1.23

39

34

... 29

$ 24

.5

:E:-

0

s"-

E

Henry-Vitrac et al.

"Typical content in five industrial batches (mean± SD) and the sample used in

this study (batch 252/10/A9; Naturex). Data are expressed as 5-CQA equivalents.

inhibitory effects of a series of structurall y related compounds in Svetol, such as caffeoylquinic acids and dicaffeoylquinic acids.

**MATERIALS AND METHODS**

Chemicals. Svetol (ref. GA50107l, batch 252/IO/A9) was supplied by Natu rex (Avignon, France). Ascorbic acid, cacodylic acid, o-glucose 6-phosphate sodium salt, 5-CQA, ammonium molybdate tetrahydrate , potassium phosphate, and sodium dodecyl sulfate were purchased from Sigma (Saint Quentin Fallavier, France). Pooled human liver microsomes were obtained from BD Biosciences (Le Pont le Claix, France) and stored at -80 °C until use. Standards for caffeoylquinic and dicaffeoylquinic acids were suppli ed by Chengdu Biopurify Phytochemicals LTD (Chengdu , China).

HPLC Analysis of CGAs in Svetol. Analysis of CGAs in Svetol was performed u sing the HPLC-diode array detector gradient system (Agilent l I 00 series).The chromatographic analysis was conducted with a Zorbax Eclipse XDBC18 4.6 x *50* mm column (1.8 ,urn). The solvents were H20/ acetic acid (96:4, vfv) as solvent A and methanol/acetonitrile/acetic acid (60:10:2, vfv/v) as solvent B, at a flow rate of 1.2 mL/rnin with the following gradient: *5%* B(0-1 min), 5-15% B (l-4min), and 15-70% B (4-25 min).

Quantification was performed at optimal wavelengths (330 nm) for the

CGAs during chromatographic separation. Samples were filtered (0.45

,urn), and 2 ,uL was injected directly. The standard deviation for three

analyses of the same sample was < *5%* for all compounds. Measurement of Glc-6-Pase Activity in Microsomes. Microsomal

Glc-6-Pase activity was measured on the basis of the rate of release of phosphate under the assay conditions that were described by Waller!

eta!. *(I5).* The enzyme assays were performed at 37 ocin a final volume of

320 ,uL, containing I00 mM cacodylic acid, pH *6.5,* and concentrations of

the substrate Glc-6-P ranging from 2 to 10 mM.

The reaction was started by adding intact microsomes and was stopped

with the addition of 3.2 mL of colorimetric reagent [9 volumes of

molybdate (0.42% ammonium molybdate in I N H2S04), 2 volumes of *5%* SDS, and I volume of 10% ascorbic acid, freshly prepared and stored on ice for a maximum of 6 h]. All samples were incubated for 30 min at 45 °C, and the absorbance of the phosphate-molybdate complex was measured at 820 nm .

Microsomal intactness was quantified by measuring Man-6-Pase activity *(16).* In a preliminary study , Glc-6-Pase activity in intact human liver microsomes was determined on the basis of microsomal protein concentration and incubation time to obtain optimal experimental condi­ tions, that is, I 00*,ug* of microsomal proteins and *5* min of incubation (data not shown).

Preparation of Test Compounds.Stock solutions of test compounds

were prepared in ultrapure water (pH 6.5) and diluted with assay reagent to the final concentrations .

Data Analysis. Enzymatic activity was expressed as micromoles of phosphate released per minute per milligram of protein. Results were expressed as means ± standard deviation (SD) of three independent experiments. Percentage of inhibition of Glc-6 Pase activity was calculated

-I -0,5 0,5 1,5

Figure 1. Double-reciprocal or Lineweaver-Burk plot of inhibition of Glc-

6-P hydrolysis by Svetol in human liver microsomes . Reaction mixture (pH 6.5) contained 2.0-10.0 mM Glc-6-P with 0 C•). 0.2 (+), 0.4 **(.A),** or 0.6 mM **(e)** Svetol. Each bar represents the mean ± SD of three measure­

ments.

by dividing the initial rate of reaction in microsomes that were treated with individual compounds by the initial rate of reaction in untreated micro­ somes. The contribution of individu al CGAs lo total inhibition by Svetol was calculated on the basis of their concentrations in Svetol and their own inhibition values by dividing the percentage of inhibition of each CGA by the percentage of inhibition of 0.6 mM total CGAs from Svetol.

Statistical analysis was performed using an ANOVA test followed by a

post hoc Tukey test under a normality assumption (Shapiro Wille) or

Kruskall Wallis nonparametric test followed by Bonferroni adjusted

Mann-Whitney test otherwise;*p* < 0.05 was considered to be significant.

**RESULTS**

Determination of CGA Composition in Svetol. Svetol is a commercial unroasted and decaffein ated green *Coffea canephora* extract, standardized to contain >45% CGAs and > 10% 5- CQA . Table **1** lists the average contents and standard deviations of CGAs in five industrial batches that have been quantified as 5-CQA equivalents (batches 252fi0/A9, H43/ 17/A8, H37/40/A9, 327/23/A9, and 324/44/A9; Naturex). The sample that we used contained high levels of total CGAs (47.66% of dry weight), with a specific ratio (0.3) between 5-CQA and total CGAs.

Inhibition of Glc-6-Pase Activity by Svetol. We tested whether Svetol could inhibit the hepatic Glc-6-Pase system by measuring enzymatic activity in human liver micro somes.These experiments were conducted with or without Svetol at final CGA concentra­ tions of 0.2, 0.4, and 0.6 mM. The effect ofSvetol on Glc-6-Pase activity was tested as a function of Glc-6-P substrate concentra­ tion (2-10 mM).

The double-reciprocal plots in Figure 1 show that Svetol decreased *V*m values in a dose-dependent manner, but *Km* was unchanged. By Michaelis-Menten kinetics , Svetol inhibited Glc- 6-P hydrolysis in human liver microsomes in a significant and competitive manner (Table 2), which is consistent with previous studies of 5-CQA in rat liver microsomes *(13).*

Inhibition of Glc-6-Pase Activity by CGAs. Because studies have demonstrated that 5-CQA and its synthetic analogues inhibit Glc- 6-Pase *(13, 14,17),*we investigated whether other CGAs in coffee possess the same functions as 5-CQA. Therefore, the selected CQAs and di-CQAs were studied at their respective concen tra­ tions in Svetol (0.6 mM total CGAs) with 2 mM Glc-6-P (i.e.,

below the apparent *KrrJ* to facilitate detection of putative compe­

titive inhibitors.

Article

The percentages of inhibition of Glc-6-P hydrolysis of each compound and its contribution to the inhibitory activity ofSvetol are shown in **Table** 3. Of the three CQAs in Svetol, 4-CQA inhibited Glc-6-P hydrolysi s to the greatest extent (14% in­ hibition) . In addition, 4-CQA contributed 40% of the inhibitory effect of Svetol.

4,5-diCQA effected similar inhibition as 4-CQA (13% in­ hibition) and contributed 35% of the inhibitory effect of Svetol. We also examined inhibition by mixtures of CQAs and diCQAs (at their respective proportions in Svetol). When all CQAs and diCQAs were tested separately, we observed similar inhibition (approximately 20%). Moreover, when combined, the

**Table** 2. Kinetic Parameters of Glc-6-Pase in Human Liver Microsomes• condition *Vmax* (umoVmin/mg of protein) *KM* (mM)

control 0.095 ±0.002 2.41 ±0.33

Svetol (0.2 mM) 0.082 ± 0.003\* 2.65±0.18

Svetol (0.4 mM) 0.074 ±0.007\* 2.96±0.47

Svetol (0.6 mM) 0.068 ±0.001\* 2.99±0.25

•Data are expressed as mean of triplicate ± SO. • indicates values that are

significantly different from control *(P* < 0.001).

*J. Agric. Food Chem.,* Vol. XXX, No. XX,XXXX **C**

inhibition of Glc-6-P hydro lysis by 0.6 mM total CGAs from Svetol (36%) was recovered (35%), suggesting that no other compounds participate in Svetol-mediated inhibition .

**DISCUSSION**

Starvation and diabetes cause a 2-3-fold increase in Glc-6- Pase activity in the liver *(I8, 19),* making this enzyme system a potential target for nutritiona l compounds that are intended, for example, to suppress hepatic glucose production to ameliorate diabetic hyperglycemia. Our study details the inhibition of Glc-6- p hydrolysis in intact human liver microsomes by Svetol; Svetol was found to be a competitive inhibitor of Glc-6-Pase in a dose­ dependent manner.

Svetol is a decaffeinated green coffee extract that has a high CGA content and a specific ratio between CQAs and diCQAs. In this study, we showed that CQAs and diCQAs, at their respective concentrations in Svetol, have inhibitory effects similar to those of Svetol, suggesting that they are the compounds that are solely responsible for Svetol activity.

Our structure-activity analysis showed that variation in the position of the caffeoyl residue is important for the inhibition of Glc-6-P hydrolysis. Notably , two compounds (3-CQA and

**Table** 3. Structure, Percentage of Inhibition, and Contribution of Chlorogenic Acids to Glc-6-Pase Inhibition by Svetol8

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Compound | Structure | Concentrationtested (11M) | Percentage inhibition of G6Pase | Contribution(%) |
| 3-CQA | ·Qfr | 110 | 0 | 0 |
| 5-CQA | .... | 160 | 9.2 ± 1.4 | 25 |
| 4-CQA | -Q...-<#' | 120 | 14.4 ± 1.2 | 40 |
| 3,4-diCQA | ItO *-n\_*) *r*• ·' | 33 | 6.9 ±4.3 | 19 |
| 3,5-diCQA |  | 20 | 0 | 0 |
| 4,5-diCQA |  | 38 | 12.8±2.6 | 35 |
| ALICQA |  |  | 18.1 ± *5.5* | 50 |
| All di-CQA |  |  | 22.7 ± 1.5 | 62 |
| AIJ CQA+all di-CQA |  |  | 34.8 ± 4.0 | 96 |

•Each compound was tested at its naturally occurring concentration in 0.6 mM Svetol.

**D** *J. Agric. Food Chern.,* Vol. XXX, No. XX, XXXX

3,5-diCQA) were apparently ineffective in suppressing Glc-6-P hydrolysis, and greater inhibition was achieved with 4-CQA and 4,5-diCQA. This result suggests tha t the caffeoyl residue at position 3 has an unfavorable effect, whereas at position 4, it appears to be beneficial.

The observed 36% inhibition by Svetol should contribute to its antidiabetic, glucose-lowering effects by reducing hepatic glucose production. On the basis of these and other publi shed results *(13,14,17),*we propo se a mechanism by which Svetol acts. In combination with diet, it inhibits glucose absorption from the small intestine *(20).* Furthermore, by inhibiting Glc-6-Pase activ­ ity, Svetol could limit the release of glucose from glycogen into general circulation and prevent insubnemia , as reported in vivo with the chlorogenic acid derivative S3483 *(21, 22).*

This mechanism, however, depend s on the bioava ilability of chiorogenic acid and its isomers. In rats, Lafay et al. showed that 5-CQA is not hydrolyzed in the stomach or small intestine but is absorbed in the stomach in its intact form and as caffeic and (iso)ferubc acids in the small intestine *(23).* Recently, Farah et al. *(24)* confirmed that CQA and diCQA are differentially absorbed and metabolized throughout the entire gastrointestina l tract. In addition, Farah et al. *(24)* also provide evidence that urination is not a major excretion pathway of intact CGA compounds and their metabolites.

In conclusion, our findings engender new research opportu­ nities because they demonstrate the importance of the position of the caffeoyl residue in the inhibition of Glc-6-Pase by CGAs. Because few structure-activity relationship studies on the inhibi­ tion of Glc-6-Pase by synthetic analogues of 3-CQA exist *(14,17),* additiona l complementary studies will provide new tools for investigating the molecular structure and function of the Glc-6 Pase system.

**ABBREVIATIONS USED**

CGAs, chlorogenic acids; CQAs, caffeoylquinic acids; diC­ QAs, dicaffeoylquinic acids; FQA s, feruloylquinic acids; Glc-6- Pase, glucose-6-phosphatase; Glc-6-P, glucose-6-phosphate; ER, endoplasmic reticulum; Glc-6-PT, glucose 6-phosphate translo­ case.

**ACKNOWLEDGMENT**

We are grateful to Dr. Ray Cooke for reviewing the manuscript

and to Christophe Bulot for statistical analysis.

**LITERATURE CITED**

(I) Salazar-Martinez, E.; Willett, W. C.; Ascherio, A.; Manson, J. E.; Leitzmann, M. F.; Stampfer, M. J.; Hu, F. B. Coffee con sumption and risk for type 2 diabetes mellitus.*Ann. llllern. Med.* 2004, *140,* 1-8.

1. Agard h, E.; Carlsson, S.; Ahlborn , A .; Efendic, S.; Grill, V.; Hammar , N.; Hilding, A.; Ostenson, C. G. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women.*J. Int ern. Med.* 2004, *255,* 645-652.
2. Van Dam, R. M.; Feskens, E. J. M. Coffee consumption and risk of type 2 diabetes mellitus. *Lancet* 2002, *360,* 1477-1478.
3. Van Dijk, A. E.; Olthof, M. R.; Meeuse, J. C.; Seebus, E.; Heine, R.J.; Van Dam , R . M . Acute effects of decaffeinated coffee and the major coffee components chlorogeni c acid and trigonelline on glucose tolerance. *Diabete s Care* 2009, 32, 1023-1025.
4. Farah,A.; Donangelo, C. M. Phenolic compounds in coffee. *Braz .J.*

*Plant Physio/.* 2006, *18,* 23-36.

1. Clifford, M. N. Chlorogenic acids and other cinnamates -nature, occurrence, dietary burden, absorption and metabolism. *J.* Sci.*Food Agr ic.* 2000, *80,* 1033-1043.
2. Greenberg, J. A.;Axen , K . V.;Schnoll, R.; Boozer , C. N. Coffee, tea

and diabetes: the role of weight loss and cafeine. *Int. J. Obes.* 2005,

*29,* 1121-1 129.

Henry-Vitrac et al.

1. Naismith , D. J.; Akinyanju, P.A.; Szanto, S.; Yudkin, J. The effect, in volun teers, of coffee and decaffeinated coffee on blood glucose, insulin, plasma lipids and some factors involved in blood clotting. *N utr. Metab.* 1970, *12,* 144-151.
2. Battram , D. S.; Arthur , R .; Weekes, A.; Graham, T. E. The glucose

intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men.*J. Nutr.* 2006, *136,* 1276-1280 .

1. Dellalibera, S. 0.; Lemaire, B.; Lafay, S. Le Svetol, un extrait de cafe vert decafeine, induit une perte de poids et augmente le ratio masse maigre sur masse grasse chez des volon taires en surcharge pond erale. *Phy totherapie* 2006, *4,* 1-4.

(I I ) Csala, M.; Banhegyi, G.; Benedetti, A. Endoplasmi c reticulum : a

metabolic compartment. *FEBS Lett.* 2006, *580,* 2160-2165.

1. Mithieux , G. New knowledge regarding glucose-6 phosphatase gene and protein and their roles in the regulation of glucose metabolism. *Eur . J . En docrinol.* 1997, *136,* 137-145.
2. Arion , W. J.; Canfield , W. K.; Ramos, F. C.; Schindler, P.W.; Burger,

H. J.; Hemmerle, H.; Schuber t, G.; Below, P.; Herling, A. W. Chloro­ genic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. *Arch. Biochern. Biophys.* 1997, 339, 315-322.

1. Hemmerle, H.; Burger , H. J.; Below, P.; Sch ubert, G.; Rippel, R.; Schin dler , P. W.; Paulus, E.; Herling, A. W. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. *J. M ed. Chern.* 1997, 40, 137-145.
2. Wallert, M.A.; Foster, J. D.; Scholnick, D. A.; Olmschenk, S. M.; Kuehn, B. J.; Provost, J. J. Kinetic analysis of glucose-6-phospha­ tase: an investigative approach to carbohydrate metabolism and kinetics. *Biochem. Mol. Biol. Educ.* 2001, *29,* 199-203.
3. Arion, W. J. Measurement of intactn ess of rat liver endoplasmic

reticulum. *Methods Enzyrnol.* 1989, *174,* 58-67.

1. Arion, W. J.; Canfield ,W. K.; Ramos, F. C.;Su, M. L.;Burger , H.J .; Hemmerle , H.; Schubert, G.; Below, P.; Herling, W. Chlorogenic acid analog S3483: a potent competitive inhibitor of the hepatic and renal glucose-6-pho sphatase systems. *Arch. Biochern. Biophys.* 1998, *351, 279-285.*
2. Segal, H. L.; Washko , M. E. Studies of liver glucose 6-phosphatase.

Ill. Solubilization and properties of the enzyme from normal and

diabetic rats. *J. Bioi . Chern.* 1959, *234,* 1937-1941.

1. Arion, W. J.; Nordlie, R. C. Liver glucose-6-phosphatase and pyrophosphate-glucose phosph otransferase: effects of fasting . *Bio­ clzem. Biophys. Res. Commun.* 1965, *20,* 606-610.
2. Welsch, C.A.; Lachance, P.A.; Wasserman , B.P. Dietary phenolic compound s: inhibition of Na+·dependent o-glucose uptake in rat intestinal brush border membra ne vesicles. *J. Nut r.* 1989, *19,* 1698- 1704.
3. Herling, A. W.; Burger , H. J.; Schwab, D.; Hemmerle, H.; Below, P.;

Schubert, G. Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system. *Am. J. Physiol .* 1998, *274,* 1087-1093.

1. Sim on, C.; Herling, A. W.;Preibisch, G.; Burger, H.J.Upregula tion of hepatic glucose 6-phosphatase gene expression in rats treated with an inhibitor of glucose-6-phosphate translocase. *Arch . Biochem . Biophys.* 2000, *373,* 418-428 .
2. Lafay, S.; Gil-lzquierdo , A.; Manach, C.; Morand, C.; Besson, C.; Scalbert, A. Chlorogenic acid is absorbed in its intact form in the stomach of rats. *J. Nutr .* 2006, *136,* 1192-1197.
3. Farah, A.; Monteiro, M.; Donangelo, C. M .; Lafay, S. Chlorogenic acids from green coffee extract are highly bioavailab le in humans. *J. Nutr.* 2008, *138,* 2309-2315.

Received for review December 18, 2009. Revised manuscript received March 1, 2010. Accepted March 9, 2010. Authors' Disclosure Statement: Naturex is involved in research/development and marketing/ sales of Svetol as an ingredient for the food, cosmetic, and nutraceutical industries. Therefore, N aturex has a commercial interest in this publication. Polyphenols Biotech, the conducting laboratory, was paid by Naturex to perform and report the scientific work that formed the basis of this publication .Polyphenols Biotech and Naturex declare that the data in this publication represent a true and faithful representation of the work that was performed.